Evidence map›Paper›PMID 27623992›Full record

ArticleEpigenetics2018

Epigenetic loss of putative tumor suppressor SFRP3 correlates with poor prognosis of lung adenocarcinoma patients.

Martin Schlensog, Lara Magnus, Timon Heide, Julian Eschenbruch, Florian Steib, Maximilian Tator, Vera Kloten, Michael Rose, Erik Noetzel, Nadine T Gaisa and 2 more

Open access · bronzeAbstract read
In one paragraph

Article in Epigenetics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 23 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Wnt antagonist as therapeutic targets in ovarian cancer.The international journal of biochemistry & cell biology · 2022
    Review
  7. Article
  8. Article
  9. Article
  10. Hypermethylation ofOncology letters · 2018
    Article
  11. Article
  12. Review
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Martin Schlensoga Institute of Pathology , Medical Faculty of the RWTH Aachen University , Aachen , Germany.
Lara Magnusa Institute of Pathology , Medical Faculty of the RWTH Aachen University , Aachen , Germany.
Timon Heidea Institute of Pathology , Medical Faculty of the RWTH Aachen University , Aachen , Germany.
Julian Eschenbrucha Institute of Pathology , Medical Faculty of the RWTH Aachen University , Aachen , Germany.
Florian Steiba Institute of Pathology , Medical Faculty of the RWTH Aachen University , Aachen , Germany.
Maximilian Tatora Institute of Pathology , Medical Faculty of the RWTH Aachen University , Aachen , Germany.
Vera Klotena Institute of Pathology , Medical Faculty of the RWTH Aachen University , Aachen , Germany.
Michael Rosea Institute of Pathology , Medical Faculty of the RWTH Aachen University , Aachen , Germany.
Erik Noetzelb Institute of Complex Systems, Research Center Jülich , Jülich , Germany.
Nadine T Gaisaa Institute of Pathology , Medical Faculty of the RWTH Aachen University , Aachen , Germany.
Ruth Knüchela Institute of Pathology , Medical Faculty of the RWTH Aachen University , Aachen , Germany.
Edgar Dahla Institute of Pathology , Medical Faculty of the RWTH Aachen University , Aachen , Germany.
RWTH Aachen University · DEForschungszentrum Jülich · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Secreted frizzled related protein 3 (SFRP3) contains a cysteine-rich domain (CRD) that shares homology with Frizzled CRD and regulates WNT signaling. Independent studies showed epigenetic silencing of SFRP3 in melanoma and hepatocellular carcinoma. Moreover, a tumor suppressive function of SFRP3 was shown in androgen-independent prostate and gastric cancer cells. The current study is the first to investigate SFRP3 expression and its potential clinical impact on non-small cell lung carcinoma (NSCLC). WNT signaling components present on NSCLC subtypes were preliminary elucidated by expression data of The Cancer Genome Atlas (TCGA). We identified a distinct expression signature of relevant WNT signaling components that differ between adenocarcinoma (LUAD) and squamous cell carcinoma (LUSC). Of interest, canonical WNT signaling is predominant in LUAD samples and non-canonical WNT signaling is predominant in LUSC. In line, high SFRP3 expression resulted in beneficial clinical outcome for LUAD but not for LUSC patients. Furthermore, SFRP3 mRNA expression was significantly decreased in NSCLC tissue compared to normal lung samples. TCGA data verified the reduction of SFRP3 in LUAD and LUSC patients. Moreover, DNA hypermethylation of SFRP3 was evaluated in the TCGA methylation dataset resulting in epigenetic inactivation of SFRP3 expression in LUAD, but not in LUSC, and was validated by pyrosequencing of our NSCLC tissue cohort and in vitro demethylation experiments. Immunohistochemistry confirmed SFRP3 protein downregulation in primary NSCLC and indicated abundant expression in normal lung tissue. Two adenocarcinoma gain-of-function models were used to analyze the functional impact of SFRP3 on cell proliferation and regulation of CyclinD1 expression in vitro. Our results indicate that SFRP3 acts as a novel putative tumor suppressor gene in adenocarcinoma of the lung possibly regulating canonical WNT signaling.

Indexed as

A549 CellsAdenocarcinoma of LungCarcinoma, Non-Small-Cell LungCell ProliferationCyclin D1DNA MethylationEpigenesis, GeneticFemaleFrizzled-Related ProteinsGene Expression Regulation, NeoplasticGenes, Tumor SuppressorHumansIntracellular Signaling Peptides and ProteinsMalePrognosisProgression-Free SurvivalCyclin D1Frizzled-Related ProteinsIntracellular Signaling Peptides and ProteinsDNA methylationLung cancerNSCLCSFRP3WNT signaling

Identifiers

PMID27623992
PMCPMC5997146
OpenAlexW2520715551

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.